Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wills Eye
With
Genentech, Inc.
Novartis Pharmaceuticals
This is an open-label, single center trial with two arms for patients who underwent guarded filtration surgery to control glaucoma. The control will consist of patients randomly assigned to receive inter-operative mitomycin C 0.4 mg/ml which is applied in a standard fashion with a soaked pledget inserted in the sub-tenon's space during surgery. The study arm will consist of patients randomly assigned to receive a sub-tenon injection of Ranibizumab 0.5 mg/0.05mL with a 30 gauge needle on a tuberculin syringe at the termination of the surgery. No mitomycin C will be applied.
Post operative follow-up will consist of a minimum of 6 visits during a one year period.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 yrs or older
patients requiring first time glaucoma filtering surgery
phakic or pseudophakic
must provide written informed consent and comply with study assignments
You may not be if
Pregnant, lactation or premenopausal women not using adequate contraception.
Previous glaucoma surgery, tube shunt surgery, pars plana vitrectomy, scleral buckle, penetrating keratoplasty.
Abnormality preventing reliable applanation tonometry in each eye.
